A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study

2019年12月，武汉出现了一种尚未特指的肺炎，中国预示着由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的冠状病毒大流行的爆发。病原学和疾病概况，又称冠状病毒病-2019年(新冠肺炎)，已经很快被阐明；尽管对病毒传播缺乏相当大的了解。缓解和控制疫情的公共卫生措施受到稀缺性和扩大检测的阻碍。这种病毒是我们一生中传染性最强的病毒之一，被认为主要通过飞沫感染传播。病毒传播还通过空中途径和在感染的无症状时期发生，这使公共卫生措施复杂化。缺乏个人防护装备(PPE)和不同的使用策略进一步加剧了这一问题。这些现实将医护人员(HCW)置于向已知感染患者和高度怀疑新冠肺炎的接受调查人员(PUI)提供护理的风险中。我们提出了一项假设驱动期SARS-CoV-2在一个相当大的农村卫生系统和学术医疗中心的主要健康癌症护理网络(MHCCN)癌症医护人员(HCW)中的血清流行率研究。我们的研究是基于缺乏可靠的血清流行病学数据来确定我们的癌症提供者的职业暴露和SARS-CoV-2感染的风险。我们预计我们的癌症医务工作者将迅速招募(AIM 1)，并推出血清抗体(IgG/IgM)测试(AIM 2)以确定暴露情况。将完成简短的临床和职业调查。这一队列对于维持和提供有关SARS-CoV-2传播动态的信息非常宝贵，这些信息将指导对这一大流行的持续反应，特别是预期的第二波将为农村社区的癌症护理提供信息。该项目是根据NOT-CA-20-0421提交的，与根据PA-18-591提交并随后授予的父母赠款MaineHealth Lives NCORP(1UG1 CA239771-01)密切结合并捆绑在一起。

In December 2019, the emergence of an as yet uncharacterized pneumonia in Wuhan, China heralded the onset of the coronavirus pandemic caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2). The etiology and disease profile, aka Coronavirus Disease-2019 (COVID-19), has been quickly elucidated; though there is considerable lack of understanding of viral transmission. Public health measures to mitigate and contain the outbreak are hampered by scarcity and scaling up testing. The virus is among the most contagious in our lifetimes and thought to be primarily transmitted by droplet infection. Viral transmission also occurs by airborne routes and during asymptomatic periods of infection, which complicates public health measures. This is further compounded by lack of Personal Protective Equipment (PPE) and different strategies for use. These realities place Healthcare Workers (HCWs) at risk providing care to known infected patients and Persons Under Investigation (PUIs) with high suspicion of COVID-19. We propose a hypothesis-driven period sero-prevalence study of SARS-CoV-2 in MaineHealth Cancer Care Network (MHCCN) cancer Healthcare Workers (HCWs) at a sizeable rural health system and academic medical center. Our study is predicated on the lack of sound sero-epidemiological data to define occupational exposure and risk of SARS-CoV-2 infection in our cancer providers. We anticipate brisk recruitment of our cancer HCWs (Aim 1) and roll-out of a sero-antibody (IgG/IgM) test (Aim 2) to determine exposure. Brief clinical and occupational surveys will be completed. This cohort is invaluable to sustain and provide information on the SARS-CoV-2-transmission dynamics that will guide continued response to this pandemic, especially with an anticipated second wave that will inform cancer care in the rural community setting. This project is submitted in response to NOT-CA-20-0421 and is closely integrated and tethered to MaineHealth Lifespan NCORP (1UG1 CA239771-01) the parent grant that was submitted and subsequently awarded under PA-18-591.